健友股份：格拉替雷已经提交FDA审批

Core Viewpoint - The company has submitted its drug, Glatiramer, for FDA approval and investors are encouraged to monitor future announcements for updates [1] Group 1 - The company confirmed the submission of Glatiramer for FDA approval on December 5 [1] - Investors are advised to pay attention to the company's future announcements regarding the progress of the FDA approval [1]